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Background: Inflammation and endothelial dysfunction is implicated in the atherosclerosis initiation and
progression in the setting of hyperlipidemia. Colchicine is a potent anti-inflammatory agent and whether colchicine
combined with atorvastatin has synergistic effects on inflammation amelioration and endothelial function
improvement is unknown.
Methods: Hyperlipidemic rat model was produced by high-fat and high-cholesterol diet for 6 weeks. Rats with normal
diet were served as shame group. In hyperlipidemic group, normal saline, atorvastatin (10 mg/kg body weight/day),
colchicines (0.5 mg/kg body weight/day), or atorvastatin combined with colchicines (same dosages) were prescribed
for 2 weeks. Serum levels of lipid profile, C-reactive protein (CRP), liver enzyme, lipoprotein associated phospholipase A2
(Lp-PLA2) and nitric oxide (NO) production were serially assessed.
Results: Before the beginning of the study, all laboratory variables were comparable among each group. After 6 weeks
of hyperlipidemic model production, serum levels of cholesterols, CRP and Lp-PLA2 were significantly increased when
compared to sham group, whereas NO production was reduced. With 2 weeks of colchicine therapy, serum levels of
CRP and Lp-PLA2 were decreased and NO production was enhanced in the colchicine group in a lipid-lowering
independent manner. Added colchicine into atorvastatin therapy further improved NO production and decreased CRP
and Lp-PLA2 levels, indicating a potential synergism of colchicine and atorvastatin.
Conclusion: Colchicine combined with atorvastatin may have stronger protective effects on improving endothelial
function and ameliorating inflammation in rats with hyperlipidemia.
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Hyperlipidemia is a major cause of multiple diseases
such as atherosclerotic cardiovascular diseases (CVD)
[1,2]. The mechanisms of hyperlipidemia implicated in
the initiation and progression of CVD predominantly
involve sustained endothelial dysfunction and vascular
inflammation [3-5]. Previously, many animal studies
and clinical trials also have consistently demonstrated
that with statins therapy, a potent agent in regulating
lipid metabolism, not only lipid profile disorder has
been corrected but also systemic inflammation is* Correspondence: huangcw@vip.sina.com; chengxuwang123@163.com
1The Department of Internal Medicine, the Second Affiliated Hospital of
Shantou University, Shantou, China
3The Emergency Department, the Second Affiliated Hospital of Dalian
Medical University, Dalian, China
Full list of author information is available at the end of the article
© 2014 Huang et al.; licensee BioMed Central
Commons Attribution License (http://creativec
reproduction in any medium, provided the or
Dedication waiver (http://creativecommons.or
unless otherwise stated.ameliorated as indicated by the decrease of inflamma-
tory cytokines such as C-reactive protein (CRP) [6-9].
Lipoprotein associated phospholipase A2 (Lp-PLA2)
is a key enzyme responsible for degrading platelet-
activating factor (PAF) and oxidated-LDL (ox-LDL). Ini-
tially, some basic studies showed that Lp-PLA2 was
beneficial for deterring atherosclerosis progression by
means of degrading PAF, a potent pro-inflammatory
cytokine [10-12]. Nevertheless, thereafter, a large number
of clinical and experimental studies have consistently
revealed that increased Lp-PLA2 level was associated with
increased risk of cardiovascular events [13-15], which was
considered to be associated with the increased production
of lyso-phosphotidylcholine (Lyso-PC) and oxidized
non-esterified fatty acids (oxNEFAs), two potent pro-
inflammatory and pro-atherosclerotic intermediates
derived from ox-LDL degradation by Lp-PLA2 [16,17].Ltd. This is an Open Access article distributed under the terms of the Creative
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effects on reducing Lp-PLA2 level [18-20], nonethe-
less, other studies showed no favorable effects of sta-
tins on Lp-PLA2 reduction [21,22]. Therefore, whether
statins can reduce Lp-PLA2 is still inconclusive.
Colchicine is an old medicine and has been used for
gout and other inflammatory diseases due to its potent
effect on improving inflammatory reactions. Recently,
a study conducted by Nidorf and colleagues showed
that colchicine combined with statins was beneficial
for cardiovascular events’ prevention [23]. The under-
lying mechanisms are far from clear, however. Previ-
ously, one study revealed that colchicine could inhibit
adhesion of neutrophilic granulocytes to epidermal
sections induced by PAF [24]. Since most of circulating
Lp-PLA2 is produced by macrophages within vascular
wall [17], therefore, we hypothesized that colchicine
might reduce Lp-PLA2 production through inhibiting
leukocytes adhesion and infiltration.
Taken together, in light of the crucial roles Lp-PLA2
plays on the initiation and progression of vascular inflam-
mation and atherosclerosis in subjects with hyperlipidemia
and the potent effect of colchicine on regulating inflam-
mation, we hypothesized that colchicine might be effective
in ameliorating vascular inflammation and improving
endothelial function by means of declining Lp-PLA2 level,
and if corroborated, we believed that in the future adds
colchicines into statins therapy may have additional bene-
fits on CVD prevention and therapy.Methods
Animal model and study protocol
Male Sprague–Dawley (SD) rats weighing 200-220 g
were obtained from Experimental Animal Center of
Shantou University, Shantou, China. The study was ap-
proved by Ethic Committee of Shantou University. To-
tally 50 rats were used in current study and after
1 week’s accommodation were evenly and randomly di-
vided into 5 groups. Ten rats given normal diet were
served as sham group, and the other 40 rats were given
a high-fat and high-cholesterol diet as described by pre-
vious study with mild modification (cholesterol 4%, cholic
acid 0.4%, propylthiouracilum 0.3% and lard 10%) for
6 weeks for hyperlipidemic model production [25]. Subse-
quently, the 40 hyperlipidemic rats were randomly and
evenly assigned into 4 groups as follow: control group was
orally given normal saline, statins group orally given atorva-
statin (10 mg/kg body weight/day, reconstituted in normal
saline), colchicine group intraperitoneally injected colchi-
cine (0.5 mg/kg body weight/day, dissolved in 0.05%
dimethyl sulfoxide, DMSO), and combined group given
atorvastatin and colchicine as described above. Total inter-
vention duration was 2 weeks.Laboratory examination
Fasting blood was taken for laboratory examination be-
fore the beginning of the study, after 6 weeks of model
production, and after 2 weeks of intervention. The vari-
ables for examination involved serum levels of triglycer-
ide (TG), total cholesterol (TC), low density lipoprotein
cholesterol (LDL-C), high density lipoprotein cholesterol
(HDL-C), alanine aminotransferase (ALT), aspartate ami-
notransferase (AST) and CRP, which were assessed by
Automatic Biochemistry Analyzer (Hitachi 7150, Tokyo,
Japan). Serum level of nitric oxide (NO) was evaluated by
nitrite reductase method using Total Nitric Oxide Kit
(Beyotime, Haimen, China, S0023), and serum level of Lp-
PLA2 was assessed by sandwich enzyme-linking immune-
sorbent assay (ELISA) kit (Yanjin Biochemistry Company,
Shanghai, China). Three independent experiments were
performed in duplicate.
Statistical analyses
All continuous variables were expressed as mean ± SD, and
analyses were performed with SPSS software, version 18.0
(SPSS Science, Chicago, IL, USA). Statistical significance
among groups was evaluated with One Way ANOVA (post
hoc LSD-t), and a value of P < 0.05 was considered statisti-
cally significant.Results
Changes of lipid profile and other variables
As presented in Table 1, the baseline laboratory variables
among different groups were comparable at the very be-
ginning, and after 6 weeks of high-fat and high-cholesterol
diet administration, the serum levels of TG, TC and LDL-
C in hyperlipidemic model groups were significantly in-
creased when compared to the sham group. Additionally,
serum level of CRP was also profoundly increased in
hyperlipidemic model groups, indicating that hyperlipid-
emia was significantly associated with systemic inflamma-
tion. After two weeks’ intervention, serum levels of TC
and LDL-C in the atorvastatin and combined groups were
significantly reduced and no changes were found in the
control and colchicine groups. When compared to the
atorvastatin group, CRP reduction was more prominent in
the colchicine group (5.35 ± 0.93 mg/L versus 4.03 ±
0.65 mg/L, P < 0.05), indicating that colchicine might have
more robust effect on ameliorating inflammation than
atorvastatin, which was independent of lipid-lowering. Im-
portantly, this anti-inflammatory effect of colchicine was
further enhanced when combined with atorvastatin as evi-
denced by the magnitude of CRP reduction in the com-
bined group was more prominent than the other groups.
Notably, no liver toxicity was found in each group, indicat-
ing that current used dosage of atorvastatin and/or colchi-
cine was safe for 2 weeks’ therapy in rats.
Table 1 Changes of lipid profile and other variables (n = 10, each group)
Variables Sham Control Atorvastatin Colchicine Combined
Before the beginning of the study
TG (mmol/L) 0.93 ± 0.11 0.98 ± 0.14 0.93 ± 0.12 0.95 ± 0.10 0.96 ± 0.15
TC (mmol/L) 3.04 ± 0.35 3.11 ± 0.32 3.08 ± 0.27 3.06 ± 0.30 3.09 ± 0.33
LDL-C (mmol/L) 1.99 ± 0.24 1.98 ± 0.21 2.01 ± 0.29 1.97 ± 0.19 2.01 ± 0.24
HDL-C (mmol/L) 1.03 ± 0.08 1.03 ± 0.07 1.05 ± 0.07 1.04 ± 0.06 1.04 ± 0.05
CRP (mg/L) 1.24 ± 0.16 1.27 ± 0.13 1.32 ± 0.16 1.25 ± 0.19 1.24 ± 0.13
ALT (U/L) 24.5 ± 3.8 25.8 ± 3.0 25.2 ± 1.9 24.2 ± 1.7 26.0 ± 2.8
AST (U/L) 28.3 ± 2.3 27.6 ± 2.7 28.2 ± 2.4 29.1 ± 3.2 28.8 ± 2.5
6 weeks of model production
TG (mmol/L) 0.98 ± 0.13* 2.15 ± 0.33 2.22 ± 0.37 2.19 ± 0.28 2.20 ± 0.27
TC (mmol/L) 3.08 ± 0.32* 5.87 ± 0.66 5.93 ± 0.61 5.91 ± 0.57 5.89 ± 0.60
LDL-C (mmol/L) 1.97 ± 0.21* 3.76 ± 0.55 3.79 ± 0.53 3.80 ± 0.51 3.78 ± 0.52
HDL-C (mmol/L) 1.05 ± 0.06 1.07 ± 0.04 1.08 ± 0.02 1.07 ± 0.04 1.06 ± 0.03
CRP (mg/L) 1.30 ± 0.13* 7.25 ± 1.08 7.20 ± 1.03 7.18 ± 1.08 7.22 ± 1.05
ALT (U/L) 27.8 ± 3.2 29.2 ± 3.6 28.5 ± 2.4 26.2 ± 1.4 26.8 ± 2.0
AST (U/L) 28.2 ± 3.5 28.2 ± 2.5 28.7 ± 2.0 28.3 ± 2.7 27.4 ± 1.9
2 weeks of therapy
TG (mmol/L) 0.98 ± 0.13* 2.13 ± 0.25 1.98 ± 0.16 2.11 ± 0.22 1.97 ± 0.16
TC (mmol/L) 3.05 ± 0.24* 5.65 ± 0.48# 4.85 ± 0.41 5.85 ± 0.55& 4.64 ± 0.43
LDL-C (mmol/L) 1.93 ± 0.20* 3.70 ± 0.51# 2.92 ± 0.22 3.71 ± 0.38& 2.88 ± 0.25
HDL-C (mmol/L) 1.05 ± 0.03 1.06 ± 0.05 1.11 ± 0.03 1.08 ± 0.03 1.12 ± 0.03
CRP (mg/L) 1.32 ± 0.12* 7.19 ± 1.02# 5.35 ± 0.93 4.03 ± 0.65& 2.87 ± 0.45※
ALT (U/L) 26.3 ± 4.1 27.8 ± 1.4 28.2 ± 2.6 27.4 ± 1.8 26.3 ± 2.5
AST (U/L) 27.4 ± 3.0 27.6 ± 2.1 28.2 ± 2.4 28.0 ± 2.1 27.3 ± 1.4
Denote: *P < 0.05 versus other groups; #P < 0.05 versus Atorvastatin and Combined groups; &P < 0.05 versus Atorvastatin and Combined groups; ※P < 0.05 versus
Control, Atorvastatin and Colchicine groups.
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As presented in Table 2, after 6 weeks of high-fat and
high-cholesterol diet administration, NO production in
the hyperlipidemic model groups were significantly abol-
ished when compared to the sham group, whereas serum
levels of Lp-PLA2 were significantly elevated, indicatingTable 2 Changes of NO production and serum level of Lp-PLA
Variables Sham Control
Before the beginning of the study
NO (μmol/L) 8.6 ± 0.7 8.9 ± 0.7
Lp-PLA2 (ng/mL) 73.6 ± 6.7 78.7 ± 7.
6 weeks of model production
NO (μmol/L) 8.2 ± 0.4* 4.3 ± 0.5
Lp-PLA2 (ng/mL) 77.2 ± 8.1* 164.2 ± 1
2 weeks of therapy
NO (μmol/L) 8.9 ± 0.5 4.4 ± 0.6
Lp-PLA2 (ng/mL) 80.1 ± 9.6 160.6 ± 1
Denote: *P < 0.05 versus other groups; #P < 0.05 versus Atorvastatin, Colchicine and
groups.that hyperlipidemia might not only contribute to enhanced
inflammation but also impaired endothelial function. After
2 weeks of treatment, NO production in the atorvastatin,
colchicine and combined groups were increased when
compared to the control group, and additionally the serum
levels of Lp-PLA2 were concomitantly decreased. When2
Atorvastatin Colchicine Combined
9.2 ± 0.5 9.0 ± 0.6 8.8 ± 0.6
3 74.5 ± 6.6 76.2 ± 6.9 76.0 ± 5.7
4.1 ± 0.4 4.4 ± 0.6 4.5 ± 0.6
3.5 168.7 ± 11.5 170.3 ± 15.2 166.8 ± 14.3
# 6.2 ± 0.7 6.1 ± 0.4 7.3 ± 0.3※
0.2# 148.3 ± 9.9 143.2 ± 8.6 130.2 ± 5.8※
Combined groups; ※P < 0.05 versus Control, Atorvastatin and Colchicine
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PLA2 reduction was a little bit larger in the colchicine
group, although there was no significant difference
(143.2 ± 8.6 ng/mL versus 148.3 ± 9.9 ng/mL, P = 0.063),
and NO production between atorvastatin and colchicine
groups was also comparable (6.2 ± 0.7 μmol/L versus 6.1 ±
0.4 μmol/L, P = 0.106). Notably and interestingly, not only
NO production was more profoundly increased, but Lp-
PLA2 reduction was also more prominent in the combined
group in comparison of the other hyperlipidemic groups,
indicating that the combination of atorvastatin and colchi-
cine had synergistic effects in rats with hyperlipidemia.
Discussion
Our current study shows that in rats with hyperlipidemia,
an early stage of atherosclerosis, colchicine therapy alone
is potential in simultaneously ameliorating inflammation
and improving endothelial function, which is independent
of lipid-lowering. The effects of CRP and Lp-PLA2 reduc-
tion and NO production are further enhanced when ator-
vastatin combined with colchicine therapy, indicating that
these two drugs may have synergistic benefits on deterring
atherogenesis and atherosclerotic progression.
Hyperlipidemia, which is characterized by increased
LDL-C and TC levels and/or decreased HDL-C level, is a
major risk factor for CVD. The underpinning mechanisms
by which hyperlipidemia contributing to atherogenesis and
atherosclerotic progression involve impairing endothelial
function and eliciting endothelial activation, increasing
foam cells formation, and enhancing vascular inflammation
[4,26,27]. Therefore, treating hyperlipidemia with medica-
tions such as statins is favorable for ameliorating vascular
inflammation, improving endothelial function and deter-
ring atherosclerosis. As shown in our current study, in rats
with hyperlipidemia producing by high-fat and high-
cholesterol diet, 2 weeks of atorvastatin (10 mg/kg/day)
therapy significantly improved dyslipidemia and reduced
CRP level, which was consistent with previous finding [9].
Expectedly, the traditional potent anti-inflammatory medi-
cine colchicine also had a robust effect on declining serum
CRP level, which was independent of lipid-lowering. As is
well known that, increased CRP level is a significant risk
factor for adverse cardiovascular outcomes as strongly sup-
ported by the JUPITER trial in which, when compared to
placebo therapy, rosuvastatin significantly reduces adverse
cardiovascular events in participants with normal lipid pro-
file but with increased CRP level [28]. Our current study
showed that the efficacy of statins on CRP reduction was
further enhanced by colchicine addition suggesting that
these two medications may have synergistic effects on im-
proving systemic inflammation and may also have add-
itional benefits for cardiovascular events prevention.
As is well documented that endothelial dysfunction, in
terms of reduced NO production, plays critical roles onatherosclerosis initiation and progression [29], and add-
itionally, as Lp-PLA2 elevation has been recognized as a
new target for therapy in patients with CVD [30], we fur-
ther investigated the effects of colchicine on endothelial
function and Lp-PLA2 level. Previously, some studies have
been conducted to evaluate the effects of statins on serum
Lp-PLA2 level, and the results indicated that statins had
modest effect on Lp-PLA2 reduction, and currently two
large randomized controlled phase-III clinical trials (STA-
BILITY and SOLID-TIMI 52) are ongoing to evaluate the
efficacies of darapladib (a specific inhibitor for Lp-PLA2)
on cardiovascular outcomes, which we believe may shift
the paradigm of CVD therapy in the future due to the
highly sensitive and specific characteristic of Lp-PLA2 for
vascular inflammation. The results from our current study
indicated that colchicine has a marginally better effect on
Lp-PLA2 reduction than atorvastatin (143.2 ± 8.6 ng/mL
versus 148.3 ± 9.9 ng/mL, P = 0.063). In light of the mech-
anisms of actions of colchicine [31], we speculated that
the efficacy of colchicine on Lp-PLA2 reduction might be
at least partially associated with its effects on inhibiting in-
flammatory cells migration and infiltration. Since circulat-
ing Lp-PLA2 is largely produced by macrophages within
vascular wall, therefore, inhibiting leukocytes adhesion
and activation by colchicine was favorable for reducing
Lp-PLA2 production. Additionally, increased NO produc-
tion, which we considered derived from vascular inflamma-
tion amelioration, by colchicine therapy might reciprocally
contribute to Lp-PLA2 production. Since NO could dimin-
ish oxidative stress and reduce ox-LDL production, which
in turn leads to decrease foam cells formation and Lp-
PLA2 excretion by macrophages and foam cells [29,32].
Taken together, we believed that colchicine reducing Lp-
PLA2 production was dependent on its effects on amelior-
ating inflammation and improving endothelial function.
Importantly, NO production and Lp-PLA2 reduction were
more prominent in colchicine combined with atorva-
statin therapy, indicating that adding colchicine to sta-
tins therapy might further enhance the protective
effects of statins therapy. These mechanisms might at
least partially explain the protective effect of statins
combined with colchicine therapy on reducing cardio-
vascular events in patients with stable chronic coron-
ary artery disease [23,33]. However, since the animal
model of our current study was a simple scenario in
terms of only having hyperlipidemia, whether colchicine
really has an amazing and synergistic effect on more com-
plicated conditions such as metabolism syndrome ensuing
acute myocardial infarction in which endothelial function
maybe already irreversible and inflammatory cascade
within atherosclerotic plaque maybe already uncontrol-
lable needs to be further investigated.
Finally, with regard to the potential side effects of col-
chicine combined with statins therapy, serum level of
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and after therapy, and without any significant increase of
liver enzymes was found. However, because our current
study has not detected the changes of creatinine kinase
levels, we cannot exclude the potential myopathy incidence
induced by colchicine combined with statins therapy.
Therefore, in the future to investigate whether colchicine
combined with statins would increase the risk of myopathy
is of particular importance.
Conclusion
Results from our current study show that in rats with
hyperlipidemia, colchicine therapy is beneficial for redu-
cing CRP level, increasing NO production and decreasing
Lp-PLA2 level, which is independent of lipid-lowering.
Colchicine combined with atorvastatin therapy has syner-
gistic effects on improving endothelial function and ameli-
orating inflammation which we believe may be helpful and
beneficial for future studies in exploring optimal thera-
peutic strategies for atherosclerosis and CVD preventions
in the setting of hyperlipidemia.
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